Page 9 - Initiate Phase News Today : Breaking News, Live Updates & Top Stories | Vimarsana

iShares NASDAQ Biotechnology Index Fund (NASDAQ:IBB), (ACHL) - The Daily Biotech Pulse: Negative Regulatory Tidings For Provention Bio, Celcuity Soars On In-licensing Deal, 2 IPOs

iShares NASDAQ Biotechnology Index Fund (NASDAQ:IBB), (ACHL) - The Daily Biotech Pulse: Negative Regulatory Tidings For Provention Bio, Celcuity Soars On In-licensing Deal, 2 IPOs
benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.

United statesEli lillyProvention bioOncolytics biotech incProvention bio incAclaris therapeutics incVascular biogenics ltdReneo pharmaceuticals incHealth sciences incAgency for medicinesVectivbio holdingGreenwich lifesciences incPfizer incCelcuity incKempharm incVericel corporation

iShares NASDAQ Biotechnology Index Fund (NASDAQ:IBB), ACADIA Pharmaceuticals Inc (NASDAQ:ACAD) - The Daily Biotech Pulse: FibroGen Fudges Safety Data, Novartis Strikes Cancer Drug Collaboration, Immutep Gains On Patent Award

iShares NASDAQ Biotechnology Index Fund (NASDAQ:IBB), ACADIA Pharmaceuticals Inc (NASDAQ:ACAD) - The Daily Biotech Pulse: FibroGen Fudges Safety Data, Novartis Strikes Cancer Drug Collaboration, Immutep Gains On Patent Award
benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.

Merck keytrudaEli lillyEuropean patent officeTransmedics group incIonis pharmaceuticals incRenal drug advisory committee onMerck co incPfizer incOutset medical incHomology medicines incImmutep limitedFibrogen incPanel backingArtios pharmaOffice of health technologyCirculatory systems device advisory panel

MeiraGTx Reports Fourth Quarter and Full Year 2020 Financial and Operational Results

MeiraGTx Reports Fourth Quarter and Full Year 2020 Financial and Operational Results - Preparing to Initiate Phase 3 Lumeos Clinical Trial in AAV-RPGR - Announced Positive Preliminary Clinical Data from AQUAx AAV-hAQP1 Phase 1 Trial for Treatment of Grade 2/3 Xerostomia - Completed Build of Internal cGMP Plasmid and DNA Manufacturing Facility - Strengthened Balance Sheet and Extended Cash Runway into Mid-2023 - First in-vivo Data from Riboswitch Gene Regulation Platform to be Presented in 2021 LONDON and NEW YORK, March 11, 2021 (GLOBE NEWSWIRE) MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced financial and operational results for the fourth quarter and full year ended December 31, 2020 and provided an update on recent progress.

United statesCity ofUnited kingdomBen ricklesCompany phaseNational institutes of healthJanssen pharmaceuticals incDrug administrationJanssen pharmaceutical companies of johnsonAmerican academy of ophthalmology annual meetingCorporate developmentMeiragtx holdingsEuropean society of retina specialistsPreclinical development teamsAmerican society of retina specialistsClinical development

Investegate |Hutchison China Medi Announcements | Hutchison China Medi: Final Results, Business Update and Name Change

Investegate |Hutchison China Medi Announcements | Hutchison China Medi: Final Results, Business Update and Name Change
investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.

Hong kongNew jerseyUnited statesCity ofUnited kingdomHutchison medipharmaStates europeLondon stock exchangeDrug administrationCompany to host annual results call webcastSales teamHutchison china meditech limitedLilly sales teamHutchison china meditech limited reportsFull year resultsProvides business